The herbal product will be available in the form of ointment and oral liquid. The ‘Transfer of Technology’ has been given to the AIMIL Pharmaceuticals (India) Ltd., New Delhi to manufacture and market the research product.

Leucoderma or vitiligo is an idiopathic acquired disorder of skin. Patients with vitiligo develop white spots in the skin. World wide incidence of leucoderma has been reported 1-2%. In India, its incidence is around 4-5% and in some parts of Rajasthan and Gujarat, it is more than 5-8%.

This skin disorder is considered as a social stigma in India as people confuse it with leprosy. Affected individuals remain in constant depression with the feeling of being socially outcast. There are many existing remedies of this disorder such as allopathic, surgical and adjunctive, but they are either costly or single component based, with very low level of efficacy, as patients develop blisters, edema, irritation in the skin. As a resul, most discontinue the treatment.

Scientists of DRDO say they have focused on the causes of disease (aetiology) and researched a comprehensive formulation for management of leucoderma from Himalayan herbs by exhaustive scientific studies. Clinically, the product is quite effective and helps not only in restoring the affected area but also relieves people affected from mental stress, emotional and psychological trauma.

No comments:

Post a Comment

Search this blog

Follow by Email

Followers

Google+ Followers

About Me

Am presently contributing editor to numerous international publications on business aviation, defense and commercial aviation. Also write on construction for ENR, a Mc Graw Hill publication. Travel has been a passion that I will carry with me till the end. Write for lifestyle publications and travel on a regular basis. Organise webinars and round tables on subjects I understand!Contributed to Aviation Week for 12 years writing on aviation, space, defense, overhaul and maintenance and business aviation. Was Editorial Director to 3 MRO Asia events in Singapore and Hong Kong.